Pivotal Therapeutics Inc. announced the enrollment of the first patient in Pivotal's POMEGA Phase IIa clinical trial with PVT-100. The POMEGA Phase IIa clinical trial is a double-blinded placebo controlled study in over 100 patients scheduled to undergo vascular invasive surgery for carotid endarterectomy at the University Hospital of Strasbourg, France. Patients shall be randomized to receive either Pivotal's uniquely formulated drug candidate PVT-100 or a placebo, for six consecutive weeks.

The composite primary endpoint of the trial consists of histomorphological, biochemical and immunological status of the vascular plaque.